Eplerenone Versus PDT: Comparative Study by OCTA

Federico II University

Status: Completed

Conditions: Central Serous Chorioretinopathy

Treatments: Device: The patients underwent half fluence photodynamic therapy for 6 months; Drug: Eplerenone

Study type: Observational

Funder types: Other

Identifiers

NCT05104138

1010/2021

Details and patient eligibility

About

The study aims to analyze the changes in OCTA parameters and in choroidal thickness in patients affected by central serous chorioretinopathy treated by oral eplerenone and half-fluence photodynamic therapy.

Full description

Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by serous detachment due to the dilatation and hyperpermeability of choroidal vessels resulting in the accumulation of serous fluid between the neurosensory retina and the retinal pigment epithelium.

Several studies reported the efficacy of half-fluence photodynamic therapy (PDT) and oral eplerenone in the CSC treatment inducing a reduction of the choroidal hyperpermeability and remodeling the choroidal vascularization.

This retrospective study aims to perform a quantitative analysis of retinal and CC vessel density by OCTA at baseline, 3 and 6 months in patients underwent PDT and patients underwent eplerenone.

Enrollment: 30 patients

Sex: All

Ages: 30 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age older than 30 years
• diagnosis of central serous chorioretinopathy
• treatment-naïve with half-fluence photodynamic therapy or oral eplerenone
• absence of vitreoretinal and vascular retinal diseases

Exclusion criteria

• age younger than 30 years
• absence of diagnosis of central serous chorioretinopathy
• previous treatment with half-fluence photodynamic therapy or oral eplerenone
• presence of concomitant vitreoretinal and vascular retinal diseases

Trial design

30 participants in 2 patient groups

Half fluence photodynamic therapy

Description:

Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy

Treatment:

Device: The patients underwent half fluence photodynamic therapy for 6 months

Oral Eplerenone

Description:

Patients with central serous chorioretinopathy, treated by oral eplerenone

Treatment:

Drug: Eplerenone